author-photo

Hisako Ono

Kyoto Prefectural University of Medicine

9

Papers

37

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Novel RAF/MEK inhibitor CH5126766/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer.

2021 Cancer Science
Show All
- Source
- Cite
- Save
Citations (0)
1940PA novel RAF/MEK inhibitor CH5126766 in phase I clinical trial has an effectiveness in the combination with eribulin for the treatment of triple negative breast cancer

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway

2018 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (11)
Ribosomal protein S3 regulates XIAP expression independently of the NF-κB pathway in breast cancer cells

2017 Oncology Reports
Show All
- Source
- Cite
- Save
Citations (15)